DK2388315T3 - Anvendelse af et myxomvirus, som ikke eksprimerer funktionelt M135R, til terapeutisk behandling - Google Patents

Anvendelse af et myxomvirus, som ikke eksprimerer funktionelt M135R, til terapeutisk behandling

Info

Publication number
DK2388315T3
DK2388315T3 DK11174887.7T DK11174887T DK2388315T3 DK 2388315 T3 DK2388315 T3 DK 2388315T3 DK 11174887 T DK11174887 T DK 11174887T DK 2388315 T3 DK2388315 T3 DK 2388315T3
Authority
DK
Denmark
Prior art keywords
therapeutic treatment
myxoma virus
express functional
express
functional
Prior art date
Application number
DK11174887.7T
Other languages
Danish (da)
English (en)
Inventor
John Barrett
Marianne Stanford
Grant Mcfadden
Original Assignee
Univ Western Ontario
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Western Ontario filed Critical Univ Western Ontario
Application granted granted Critical
Publication of DK2388315T3 publication Critical patent/DK2388315T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK11174887.7T 2005-03-07 2006-03-06 Anvendelse af et myxomvirus, som ikke eksprimerer funktionelt M135R, til terapeutisk behandling DK2388315T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65881605P 2005-03-07 2005-03-07
EP06705269A EP1863906A4 (en) 2005-03-07 2006-03-06 COMBINATION OF MYXOMA VIRUS AND RAPAMYCIN USED IN THERAPEUTIC TREATMENT

Publications (1)

Publication Number Publication Date
DK2388315T3 true DK2388315T3 (da) 2014-08-25

Family

ID=36952904

Family Applications (1)

Application Number Title Priority Date Filing Date
DK11174887.7T DK2388315T3 (da) 2005-03-07 2006-03-06 Anvendelse af et myxomvirus, som ikke eksprimerer funktionelt M135R, til terapeutisk behandling

Country Status (14)

Country Link
US (5) US20090035276A1 (https=)
EP (2) EP2388315B1 (https=)
JP (2) JP2008531739A (https=)
KR (1) KR101479093B1 (https=)
CN (2) CN102357104B (https=)
AU (1) AU2006222500B2 (https=)
CA (1) CA2600675C (https=)
DK (1) DK2388315T3 (https=)
IL (2) IL185376A0 (https=)
MX (1) MX2007010962A (https=)
NZ (2) NZ577283A (https=)
RU (1) RU2461630C2 (https=)
UA (1) UA96412C2 (https=)
WO (1) WO2006094385A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090035276A1 (en) 2005-03-07 2009-02-05 Robarts Research Institute Use of a combination of myxoma virus and rapamycin for therapeutic treatment
WO2007143548A2 (en) 2006-06-01 2007-12-13 Robarts Research Institute Myxoma virus mutants for cancer treatment
JP5748656B2 (ja) * 2008-05-22 2015-07-15 ジェ イル ファーマシューティカル カンパニー リミテッド 過剰増殖細胞の腫瘍抑制因子に基づいた腫瘍崩壊ウイルスに対する感受性を判定する方法
US20120100109A1 (en) * 2010-10-26 2012-04-26 Xiaoliu Zhang Method for increasing the replication of oncolytic HSVs in highly resistant tumor cells using mTOR pathway and PI3K inhibitors
WO2012171007A2 (en) 2011-06-09 2012-12-13 University Of Florida Research Foundation, Inc. Methods for treating or preventing graft versus host disease
RU2695136C1 (ru) * 2018-06-19 2019-07-22 Общество с ограниченной ответственностью Биотехнология (ООО Биотехнология) Онколитический способ терапии рака молочной железы.
EP3833367A4 (en) 2018-08-08 2022-05-11 Arizona Board of Regents on behalf of Arizona State University Method for improved poxvirus yields
CA3112788A1 (en) * 2018-09-05 2020-03-12 Arizona Board Of Regents On Behalf Of Arizona State University Oncolytic virus platform to treat hematological cancer
JP2022546985A (ja) * 2019-09-02 2022-11-10 アリゾナ・ボード・オブ・リージェンツ・オン・ビハーフ・オブ・アリゾナ・ステイト・ユニバーシティー 非許容性の癌に対する腫瘍溶解性ウイルスの感染を改善する方法および組成物
EP4041266A1 (en) * 2019-10-10 2022-08-17 Arizona Board of Regents on behalf of Arizona State University Oncolytic virus comprising immunomodulatory transgenes and uses thereof
AU2020361622A1 (en) * 2019-10-10 2022-04-28 Arizona Board Of Regents On Behalf Of Arizona State University Oncolytic viruses that express multi-specific immune cell engagers
WO2022139440A1 (ko) * 2020-12-22 2022-06-30 바이로큐어 주식회사 신규한 재조합 믹소마바이러스 및 이의 용도

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4401653A (en) * 1981-03-09 1983-08-30 Ayerst, Mckenna & Harrison Inc. Combination of rapamycin and picibanil for the treatment of tumors
US4806347A (en) 1985-12-11 1989-02-21 Schering Corporation Interferon combinations
GB9415320D0 (en) 1994-07-29 1994-09-21 Medical Res Council Cancer treatment
ATE241994T1 (de) 1996-01-25 2003-06-15 Univ Glasgow Hsv-mutant-1716 zur behandlung von mesotheliomen
EP1003894A2 (en) 1997-07-18 2000-05-31 Chiron Corporation Lentiviral vectors
US7041654B2 (en) * 1997-10-03 2006-05-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods and compositions for inducing tumor-specific cytotoxicity
CN101618049A (zh) 1997-10-09 2010-01-06 威尔斯塔特生物公司 使用病毒来治疗赘生物
US6264940B1 (en) * 1998-08-05 2001-07-24 The Research Foundation Of State University Of New York Recombinant poliovirus for the treatment of cancer
AU6175000A (en) * 1999-07-12 2001-01-30 Viron Therapeutics, Inc. Novel myxoma genes for immune modulation
BR0015491A (pt) * 1999-11-12 2002-10-15 Oncolytics Biotech Inc Métodos para tratar um distúrbio proliferativo celular mediado por ras em um mamìfero, para tratar um neoplasma tendo uma via-ras ativada em um humano, para inibir metástase de um neoplasma tendo uma via-ras ativada em um mamìfero, e para tratar um neoplasma suspeito de ter uma via-ras ativada em um mamìfero, composição farmacêutica, kit, e, método para tratar uma população de células compreendendo um neoplasma suspeito de ter uma via-ras ativada in vitro
WO2001087324A1 (en) * 2000-05-17 2001-11-22 Viron Therapeutics, Inc. Compositions and methods for promoting immunosuppression
MX368013B (es) * 2001-02-19 2019-09-13 Novartis Ag Tratamiento de cáncer.
UA77200C2 (en) * 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
KR20120002613A (ko) * 2002-08-12 2012-01-06 제네렉스, 인코포레이티드 폭스바이러스 및 암과 관련된 방법 및 조성물
JP4800924B2 (ja) * 2003-03-07 2011-10-26 ロバーツ リサーチ インスティテュート 癌および慢性ウイルス感染の治療処置のための粘液腫症ウイルスの使用
DE602004004520T2 (de) * 2003-04-22 2007-11-08 Wyeth Antineoplastische zusammensetzungen
WO2005002607A2 (en) * 2003-07-07 2005-01-13 Oncolytics Biotech Inc. Oncolytic reoviruses for the treatment of neoplasms having activated pp2a or rac
US20070207149A1 (en) * 2004-04-27 2007-09-06 Wellstat Biologics Corporation Cancer treatment using viruses and camptothecins
US20090035276A1 (en) 2005-03-07 2009-02-05 Robarts Research Institute Use of a combination of myxoma virus and rapamycin for therapeutic treatment

Also Published As

Publication number Publication date
JP5674210B2 (ja) 2015-02-25
WO2006094385A1 (en) 2006-09-14
US9987315B2 (en) 2018-06-05
CN102357104A (zh) 2012-02-22
EP2388315B1 (en) 2014-05-21
CA2600675A1 (en) 2006-09-14
NZ560840A (en) 2009-07-31
CA2600675C (en) 2015-12-15
RU2461630C2 (ru) 2012-09-20
IL185376A0 (en) 2008-02-09
AU2006222500A1 (en) 2006-09-14
JP2008531739A (ja) 2008-08-14
EP2388315A3 (en) 2012-05-02
EP1863906A4 (en) 2009-06-03
CN101137748B (zh) 2011-12-14
NZ577283A (en) 2010-11-26
CN101137748A (zh) 2008-03-05
CN102357104B (zh) 2016-01-27
US20130171106A1 (en) 2013-07-04
KR20070110423A (ko) 2007-11-16
UA96412C2 (ru) 2011-11-10
US20140134134A1 (en) 2014-05-15
HK1163175A1 (en) 2012-09-07
US20180256656A1 (en) 2018-09-13
JP2012236860A (ja) 2012-12-06
EP1863906A1 (en) 2007-12-12
US20110195050A1 (en) 2011-08-11
US20090035276A1 (en) 2009-02-05
IL208070A (en) 2015-06-30
EP2388315A2 (en) 2011-11-23
AU2006222500B2 (en) 2011-09-01
MX2007010962A (es) 2008-03-10
KR101479093B1 (ko) 2015-01-26
IL208070A0 (en) 2010-12-30
RU2007137008A (ru) 2009-04-20

Similar Documents

Publication Publication Date Title
DK2311464T3 (da) Midler til forebyggelse og behandling af lidelser, som involverer modulation af RyR-receptorerne
DK2187878T3 (da) Anvendelse af en betablokker til fremstilling af et medikament til behandling af hæmangiomer
EP1885414A4 (en) DEVICE FOR MEDICAMENT ADMINISTRATION
ES2352576T8 (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana.
DK1833799T3 (da) 3-phenyl-pyrazol derivater, som modulatorer af 5-HT-2a-serotonin receptor nyttig til behandlingen af sygdomme relateret hertil
BRPI1013394A2 (pt) "composto, composição farmacêutica, uso do composto, e, método para tratar um paciente infectado com virus da hepatite c."
DK1928438T3 (da) Anvendelse af ibudilast til behandling af stofafhængighed
CR10508A (es) Nuevo determinante de virulencia dentro de la glicoproteina estructural e2 del virus de la peste porcina clasica
LT2959894T (lt) S1p receptoriaus moduliatoriai, skirti išsėtinės sklerozės gydymui
EA201001402A1 (ru) Фармацевтические растворы, способ получения и терапевтическое применение
DK1907037T3 (da) Medikamentdispenser.
DK2058020T3 (da) Indretning til indgivelse af lægemiddel
DK2220076T5 (da) Inhibitorer af replikationen af humant immundefektvirus
DK2139483T3 (da) Kombinationsterapier, der omfatter en quinoxalin-inhibitor af PI3K-alfa, til anvendelse til behandling af cancer
PL2281830T3 (pl) Szczepionka przeciw wirusowi ospy wietrznej i półpaśca
BRPI0815773A2 (pt) composto, e, medicamento.
DK2148670T3 (da) Titrering af tapentadol
FR2928832B1 (fr) Orthese de poignet, destinee au traitement du syndrome du canal carpien
DK2051975T3 (da) Substituerede prolinamider, fremstilling deraf og anvendelse deraf som lægemiddel.
BRPI0913216A2 (pt) uso de um herpesvírus recombinante de perus, e, herpesvírus recombinante de perus.
BRPI0808246A2 (pt) "fralda descartável".
EP2023715A4 (en) Indoleamine-2,3-dioxygenase 2
BRPI0819992A2 (pt) Métodos para operar um dispositivo médico e para habilitar numerosos aspectos operacionais de um dispositivo médico, e, dispositivo médico
DK2388315T3 (da) Anvendelse af et myxomvirus, som ikke eksprimerer funktionelt M135R, til terapeutisk behandling
DE502007005902D1 (de) -methyl-19-nor-20- spirox-4-en-3-one), sowie diese enthaltende pharmazeutische präparate